看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。& H! P4 b6 Q- ?. V: \; p }
" J3 r3 C8 D5 L+ Y. \* `0 s1 G
, H7 H- d# c7 i) A2 A. ICurrently available feasibility data for possible combination strategies. 7 D' V1 @8 H1 M' R
————————————————————————————————- p7 T$ y0 j) R% n
Combination Feasibility according to preliminary data 0 z+ p c; s* B" G
——————————————————————————————————
4 f8 c, e$ u" |) Y9 kBevacizumab + sorafenib Yes, reduced dose 9 D9 ^1 B, C9 i1 G7 h
Bevacizumab + sunitinib† No ; H$ Y4 X `% f7 @; |
Bevacizumab + temsirolimus Yes 8 A& D. f1 [* n5 v; t2 P
Bevacizumab + everolimus Yes , A" @3 p( |) }# x, R& L
Sorafenib + sunitinib ? % q: l" x; j- ~3 q
Sorafenib + temsirolimus Yes, reduced dose
4 @8 p: d6 I- R4 n# I- NSorafenib + everolimus Yes, reduced dose # ^! p7 X' F# N2 h
Sunitinib + temsirolimus† No
% m g4 y" h$ r8 M: a5 \3 Z0 BSunitinib + everolimus ?
/ N: {% M; y, }+ I2 s; E/ Y+ fTemsirolimus + everolimus ? 8 P; D' F) j5 d$ `8 r
————————————————————; f$ Y- a+ w) e1 V
†Led to US FDA warning.
- V3 s9 Q, r: {6 k% f( [ `3 L. w?: As yet unattempted combination.0 S, j9 q7 @1 C# T3 y, e) c, }( H7 \
|